Manager
Thermo Fisher Scientific, Singapore
Say Li, Kong is a cancer geneticist with extensive expertise in cancer genomics and molecular diagnostics assay development. With a career spanning clinical, academic, and industry laboratories, her work focuses on translational cancer, infectious disease and pharmacogenomics studies. Say Li has held various roles, including Medical Laboratory Scientist at PathLab and Staff Scientist at Genome Institute of Singapore. Currently, she serves as a Manager at Thermo Fisher Scientific.
Say Li has been instrumental in developing molecular diagnostics assays on qPCR, point-of-care and sequencing platforms for detection of infectious disease pathogens, pharmacogenomics application and companion diagnostics assay for individualized immunotherapy. She thrived in innovation by establishing new methodology for co-detection of genomics and transcriptomics analysis within a single cell, inventing novel detection assay for circulating tumor cells and developing comprehensive plasmid control for pharmacogenomics application.
She led the Assay Verification and Validation team that has succesfully launched several products such as TrueMark™ Respiratory, Urinary, STI, Lesion and Enteric Panels, TrueMark™ PGx SNP + CNV Panels, TaqPath™ COVID-19, Flu A, Flu B, RSV Select Panel and SteriSEQ™ Rapid Sterility Testing Kit.
Throughout her career, Kong has received several prestigious awards and grants, including the Ray Wu Prize for Excellence in Life Sciences, the Best Post-doctoral Fellow Awards by the Genome Institute of Singapore, the Travel Award by Japanese Society of Medical Oncology, the Career Development Award, Strategic Positioning Fund and Accelerate Gap Fund by A*STAR, Young Individual Research Grant by National Medical Research Council and the ProtoStar Innovation Fund by Thermo Fisher Scientific.